Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

Blood

Volumn 105, Issue 8, 2005, Pages 3051-3057

  Miller, Jeffrey S ^a   Soignier, Yvette ^a   Panoskaltsis Mortari, Angela ^a   McNearney, Sarah A ^a   Yun, Gong H ^a   Fautsch, Susan K ^a   McKenna, David ^a   Le, Chap ^a   Defor, Todd E ^a   Burns, Linda J ^a   Orchard, Paul J ^a   Blazar, Bruce R ^a   Wagner, John E ^a   Slungaard, Arne ^a   Weisdorf, Daniel J ^a   Okazaki, Ian J ^a   McGlave, Philip B ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; FLUDARABINE; INTERLEUKIN 15; METHYLPREDNISOLONE; PARACETAMOL; RECOMBINANT INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE TRANSFER; ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW APLASIA; BREATHING DISORDER; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DERMATITIS; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FEVER; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HAPLOIDY; HUMAN; HUMAN CELL; HYPOXEMIA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; INSOMNIA; LEUKEMIA REMISSION; LYMPHOCYTOPENIA; MYALGIA; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NAUSEA; NEUTROPENIA; OUTPATIENT; PANCYTOPENIA; PLEURA EFFUSION; PRIORITY JOURNAL; SAFETY; SIDE EFFECT; STROKE; THROMBOCYTOPENIA; VOMITING;

EID: 20144388509     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-07-2974     Document Type: Article

References (37)

1. Miller JS. The biology of natural killer cells in cancer, infection, and pregnancy. Exp Hematol. 2001;29:1157-1168.
2. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356:1795-1799.
3. Rosenberg S, Lotze M, Muul L, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889-897.
4. Raulet DH, Held W. Natural killer cell receptors: the offs and ons of NK cell recognition. Cell. 1995;82:697-700.
5. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today. 1990;11:237-244.
6. Uhrberg M, Valiante NM, Shum BP, et al. Human diversity in killer cell inhibitory receptor genes. Immunity. 1997;7:753-763.
7. Valiante NM, Uhrberg M, Shiling HG, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity. 1997;7:739-751.
8. Lazetic S, Chang C, Houchins JP, Lanier LL, Phillips JH. Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. J Immunol. 1996;157:4741-4745.
9. Braud VM, Allan DSJ, O'Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795-799.
10. Leibson PJ. Cytotoxic lymphocyte recognition of HLA-E: utilizing a nonclassical window to peer into classical MHC. Immunity. 1998;9:289-294.
11. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells [see comments]. Nature. 1998;391:703-707.
12. Lanier LL, Corliss B, Wu J, Phillips JH. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity. 1998;8:693-701.
13. Wu J, Song Y, Bakker AB, et al. An activating Immunoreceptor complex formed by NKG2D and DAP10 [see comments]. Science. 1999;285:730-732.
14. Miller JS, Tessmer-Tuck J, Pierson BA, et al. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biol Blood Marrow Transplant. 1997;3:34-44.
15. Burns LJ, Weisdorf DJ, DeFor TE, et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant. 2003;32:177-186.
16. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100.
17. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood. 2002;100:1935-1947.
18. Miller JS, Oelkers S, Verfaillie C, McGlave P. Role of monocytes in the expansion of human activated natural killer cells. Blood. 1992;80:2221-2229.
19. Gluck WL, Hurst D, Yuen A, et al. Phase 1 studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res. 2004;10:2253-2264.
20. Prlic M, Blazar BR, Farrar MA, Jameson SC. In vivo survival and homeostatic proliferation of natural killer cells. J Exp Med. 2003;197:967-976.
21. Cooper MA, Bush JE, Fehniger TA, et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood. 2002;100:3633-3638.
22. Miller JS, McCullar V. Human NK cells with polyclonal lectin and immunoglobulin-like receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood. 2001;98:705-713.
23. Yu H, Fehniger TA, Fuchshuber P, et al. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15. Blood. 1998;92:3647-3657.
24. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97:14-32.
25. Theofilopoulos AN, Dummer W, Kono DH. T cell homeostasis and systemic autoimmunity. J Clin Invest. 2001;108:335-340.
26. Maine GN, Mule JJ. Making room for T cells. J Clin Invest. 2002;110:157-159.
27. Dummer W, Niethammer AG, Baccala R, et al. T cell homeosiatic proliferation elicits effective antitumor autoimmunity. J Clin Invest. 2002;110:185-192.
28. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
29. Fry TJ, Connick E, Falloon J, et al. A potential role for interleukin-7 in T-cell homeostasis. Blood. 2001;97:2983-2990.
30. + T cells. J Exp Med. 2001;193:219-231.
31. Mayumi T, Takezawa J, Takahashi H, et al. IL-15 is elevated in the patients of postoperative enteracolitis. Cytokine. 1999;11:888-893.
32. Mention JJ, Ben Ahmed M, Begue B, et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology. 2003;125:730-745.
33. Okazawa A, Kanai T, Nakamaru K, et al. Human intestinal epithelial cell-derived interleukin (IL)-18, along with IL-2, IL-7 and IL-15, is a potent synergistic factor for the proliferation of intraepithelial lymphocytes. Clin Exp Immunol. 2004;136:269-276.
34. Kuniyasu H, Ohmori H, Sasaki T, et al. Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis. Clin Cancer Res. 2003;9:4802-4810.
35. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208-2216.
36. + donor lymphocytes in children. Bone Marrow Transplant. 2002;29:497-502.
37. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102:814-819.